First patient dosed in phase II Telix Starburst trial

2019 04 22 18 32 5246 Pet Ct Machine 400

The first patient has been dosed in Telix Pharmaceuticals' carbonic anhydrase-(CAIX)-targeting PET/CT imaging agent TLX250-CDx (zirconium-89 DFO-girentuximab) trial.

The phase II trial, called Starburst, is intended to investigate the diagnostic and therapeutic efficacy of the agent for a variety of cancers, including breast, cervix, colorectal, gastric, esophageal, head and neck, lung, ovarian, pancreatic, and vulval, according to the firm.

Page 1 of 653
Next Page